Clinical Trial: A Single-arm, Single-center Phase II Clinical Study of SBRT Combined with Aparlimab and Platinum-based Doublet Induction Therapy Followed by Concurrent Chemoradiotherapy plus Aparlimab Consolidation Therapy as First-line Treatment for Limited-stage Small Cell Lung Cancer (China)

China, Aug. 18 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A Single-arm, Single-center Phase II Clinical Study of SBRT Combined with Aparlimab and Platinum-based Doublet Induction Therapy Followed by Concurrent Chemoradiotherapy plus Aparlimab Consolidation Therapy as First-line Treatment for Limited-stage Small Cell Lung Cancer'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130204

Registration Time: 2026/08/17

Type: Interventional study

Primary Sponsor: Shanghai Pulmonary Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=335937

Published by HT Digital Content Services with permission from Health Dail...